Stay updated on Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial
Sign up to get notified when there's something new on the Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial page.

Latest updates to the Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 added to the page. The lapse-in-funding notice and the Revision: v3.4.1 entry have been removed.SummaryDifference0.3%

- Check21 days agoChange DetectedA government funding notice was added noting potential processing delays and that the NIH Clinical Center is open, and the page was updated from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check28 days agoChange DetectedAdded a 'Show glossary' control and updated QC-related labels to 'Last Update Submitted that Met QC Criteria' and 'Revision: v3.4.0', while removing the older 'Last Update Submitted that met QC Criteria', 'No FEAR Act data', and 'Revision: v3.3.4'.SummaryDifference0.1%

- Check35 days agoChange DetectedRevision: v3.3.4 added and Revision: v3.3.3 removed on the page. This appears to be a minor documentation update without affecting study details or results.SummaryDifference0.0%

- Check64 days agoChange DetectedA full list of trial locations across US states and Canadian provinces was added and the revision updated to v3.3.3, while prior location blocks and the HHS Vulnerability Disclosure entry were removed.SummaryDifference2%

- Check85 days agoChange DetectedThe page footer updated from Revision: v3.3.1 to Revision: v3.3.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

Stay in the know with updates to Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Dose Ranging Study of GSK1265744 Plus NRTIs in HIV-1 Clinical Trial page.